)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Intensity Therapeutics
Intensity Therapeutics (INTS) investor relations material
Intensity Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary27 Mar, 2026
Executive summary
Raised over $20 million in gross proceeds in 2025, ending the year with $11.9 million in cash and cash equivalents, providing a cash runway into Q2 2027.
Published IT-01 Study results in eBioMedicine, showing promising disease control and survival data for INT230-6 in refractory metastatic cancer.
Reported favorable efficacy and safety for INT230-6 in triple negative breast cancer patients in the INVINCIBLE-4 Study.
Financial highlights
Research and development expenses were $6.8 million for 2025, down from $10.5 million in 2024, mainly due to lower clinical trial and manufacturing costs.
General and administrative expenses were $5.2 million for 2025, down from $6.1 million in 2024, reflecting cost efficiencies.
Net loss for 2025 was $11.6 million, compared to $16.3 million in 2024.
Cash and cash equivalents totaled $11.9 million as of December 31, 2025.
Outlook and guidance
Plans to resume patient enrollment and site activations in paused clinical studies during 2026, contingent on securing additional funding.
Cash runway is expected to last into the second quarter of 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Intensity Therapeutics
- Directors re-elected, stock plan approved, and auditor ratified with no Q&A from shareholders.INTS
AGM 20243 Feb 2026 - Shelf registration enables up to $150M in offerings, supporting late-stage oncology trials.INTSRegistration Filing16 Dec 2025
- Registering 394,500 shares for resale; lead cancer drug advancing to Phase 3.INTSRegistration Filing16 Dec 2025
- Shareholders to vote on a reverse stock split and potential adjournment to maintain Nasdaq compliance.INTSProxy Filing2 Dec 2025
- Shareholders will vote virtually on director election and auditor ratification, with board approval recommended.INTSProxy Filing2 Dec 2025
- Annual meeting to vote on directors, ESPP, and auditor, with all proposals board-recommended.INTSProxy Filing2 Dec 2025
- Stockholders will vote virtually on a reverse stock split to address Nasdaq compliance.INTSProxy Filing2 Dec 2025
- Vote on director elections, stock plan, and auditor ratification at the July 17 virtual meeting.INTSProxy Filing2 Dec 2025
- Key votes include a reverse stock split and possible meeting adjournment, both board-recommended.INTSProxy Filing2 Dec 2025
Next Intensity Therapeutics earnings date
Q1 202611 May, 2026
Intensity Therapeutics
Next Intensity Therapeutics earnings date
Q1 202611 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage